About UW Medicine Anticoagulation Services

This website contains UWMedicine recommendations, guidelines and protocols for the treatment and prevention of venous and arterial thrombosis, and the clinical use of antithrombotic agents in ambulatory and inpatient settings.

UWMedicine Anticoagulation Services is operated by the UWMedicine Department of Pharmacy, and collaborates with multidisciplinary specialties and providers  across UWMedicine to develop and disseminate guidelines and to coordinate the use of antithrombotic agents across the UWMedicine enterprise.  

UWMedicine Anticoagulation Services also provides management of anticoagulant therapy in pharmacist-managed anticoagulation clinics at the University of Washington Medical Center (UWMC) , Seattle Cancer Care Alliance (SCCA) and Harborview Medical Center (HMC).  Pharmacist providers in these clinics are involved in clinical practice, training and education, and research activities consistent with the mission of UW Medicine and the Department of Pharmacy.

"The goals of pharmacist-managed anticoagulation services include treatment and prevention of thromboembolic disease and minimization of complications of antithrombotic therapy."

Use the links to the left to navigate through the major sections of this site. The links at the top are the most frequently visited areas. BY USING THE SITE, YOU AGREE TO THE TERMS OF USE; IF YOU DO NOT AGREE, DO NOT USE THE SITE.

 

 

REVISED GUIDELINES - Mechanical Circulatory Support Anticoagulation Guidelines

In December 2016, the Mechanical Circulatory Support Anticoagulation Guidelines were revised. The update is posted on the MCS Website and on the UWMedicine Anticoagulation Services website.

REVISED GUIDELINES - VTE Prophylaxis Guidelines by Clinical Group

In November 2016, UWMedicine VTE Prophylaxis Guidelines by Clinical Group were revised to reflect changes in practice related to Harborview Medical Center trauma patients (trauma, acute spinal cord injury and spine fracture repair, regardless of covering service).

REVISED GUIDELINES - Recommendations for Chronic Antithrombotic Therapy

In September 2016, a revision to UWMedicine Recommendations for Chronic Antithrombotic Therapy was posted, to highlight updates  in guidelines from various sources.

REVISED GUIDELINES - Neuraxial Procedures and Anticoagulation

In March 2016, the UWMedicine guidelines on Management of Antithrombotic Therapy for Neuraxial Procedures were revised by the Dept of Anesthesia and Pain Medicine, the Dept of Pharmacy, and UWMedicine Anticoagulation Services. Please find the revised guidelines in the section titled Peri-Procedural Anticoagulation Management.

NEW GUIDELINES - Perioperative Management of Antiplatelet Therapy

In March 2016, new UWMedicine guidelines for Perioperative Management of Antiplatelet Therapy in Patients Undergoing Non-Cardiac Surgery/Procedures were approved. The link to these guidelines can be found in the section titled Peri-Procedural Anticoagulation

NEW GUIDELINES - Management of Antithrombotic Therapy for Chronic Pain Procedures

In February 2016, UWMedicine guidelines for Management of Antithrombotic Therapy for Chronic Pain Procedures were completed. These guidelines were developed by the members of the Dept of Anesthesiology and Pain Medicine, the Dept of Pharmacy, and UWMedicine Anticoagulation Services.   The guidelines can be found in the section on website section titled Peri-Procedural Anticoagulation

NEW - Patient Education Materials

Three new UWMedicine patient education brochures were added in February 2016, including:

- Medications to Avoid Before Surgery: when your doctor tells you to avoid certain medicines or supplements to prevent bleeding problems

- Preventing Blood Clots: while you are in the hospital -

-Treating Blood Clots: Deep vein thrombosis and pulmonary embolism, and how they are treated

NEW CONTENT - IDARUCIZUMAB

Idarucizumab (Praxbind) is a reversal agent for dabigatran. It was approved by the UWMedicine Pharmacy and Therapeutic Committee in January 2016 for reversal of dabigatran in the setting of life-threatening bleeding or emergency surgery. The UWMedicine Guidelines for Reversal of Anticoagulants and Guidelines for Reversing Coagulopathies in Patients with Spontaneous IPH have been revised to relect its availability.

UPDATE: Treatment of Acute Venous Thromboembolism

In January 2016, UWMedicine Guidelines for Treatment of Acute Venous Thromboembolism were updated. The new guidelines reflect the preference for DOACs vs traditional LMWH/warfarin for treatment of DVT and PE, as recommended in the 2016 Antithrombotic Therapy for VTE Disease/ Chest Guideline from the American College of Chest Physicians.

Pages